Q2 EPS Estimate for Kymera Therapeutics Boosted by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at B. Riley boosted their Q2 2025 earnings per share (EPS) estimates for shares of Kymera Therapeutics in a research note issued on Monday, May 12th. B. Riley analyst K. Patel now anticipates that the company will post earnings of ($1.01) per share for the quarter, up from their previous estimate of ($1.02). The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ Q3 2025 earnings at ($1.00) EPS, Q4 2025 earnings at ($1.03) EPS, FY2025 earnings at ($3.85) EPS, FY2026 earnings at ($3.88) EPS, FY2027 earnings at ($3.88) EPS and FY2028 earnings at ($3.80) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics’s quarterly revenue was up 114.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.69) EPS.

KYMR has been the subject of a number of other reports. Stephens reissued an “overweight” rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Guggenheim reiterated a “buy” rating and set a $52.00 price objective on shares of Kymera Therapeutics in a report on Monday. HC Wainwright increased their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. UBS Group dropped their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Citigroup started coverage on Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 target price on the stock. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $55.27.

Kymera Therapeutics Stock Down 4.5%

Shares of NASDAQ KYMR opened at $29.75 on Wednesday. Kymera Therapeutics has a twelve month low of $19.45 and a twelve month high of $53.27. The company’s fifty day moving average is $29.48 and its 200-day moving average is $37.31. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -12.71 and a beta of 2.18.

Insider Transactions at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now owns 80,085 shares in the company, valued at approximately $2,438,588.25. This trade represents a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the transaction, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 10,659 shares of company stock worth $324,567 in the last 90 days. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

Hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. raised its stake in Kymera Therapeutics by 35.1% in the 3rd quarter. Franklin Resources Inc. now owns 29,440 shares of the company’s stock valued at $1,356,000 after acquiring an additional 7,647 shares during the period. JPMorgan Chase & Co. boosted its position in Kymera Therapeutics by 212.6% during the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company’s stock worth $6,649,000 after purchasing an additional 95,547 shares during the period. Blue Trust Inc. increased its holdings in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV increased its holdings in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Kymera Therapeutics by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,733 shares of the company’s stock valued at $552,000 after purchasing an additional 1,311 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.